Literature DB >> 16893349

Prevention and treatment of post-traumatic epilepsy.

Carlo Alberto Pagni1, Francesco Zenga.   

Abstract

Post-traumatic epilepsy is reported after 2-5% of closed head injuries but up to 50% or more following penetrating head injury. Despite several studies, no drug strategy has been able, to date, to quench the biochemical events leading to epileptogenesis. One possibility is that treatment with available antiepileptic drugs has been implemented too late, and thus, ultra-early treatment might still be able to stop the neurochemical epileptogenic cascade dead in its tracks. However, currently drug therapy should be instituted only after the first late unprovoked seizure.

Entities:  

Mesh:

Year:  2006        PMID: 16893349     DOI: 10.1586/14737175.6.8.1223

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  5 in total

1.  Correlates of posttraumatic epilepsy 35 years following combat brain injury.

Authors:  V Raymont; A M Salazar; R Lipsky; D Goldman; G Tasick; J Grafman
Journal:  Neurology       Date:  2010-07-20       Impact factor: 9.910

Review 2.  Neuroimaging biomarkers of epileptogenesis.

Authors:  Asht Mangal Mishra; Harrison Bai; Alexandra Gribizis; Hal Blumenfeld
Journal:  Neurosci Lett       Date:  2011-02-16       Impact factor: 3.046

Review 3.  Global expression profiling in epileptogenesis: does it add to the confusion?

Authors:  Yi Yuen Wang; Paul Smith; Michael Murphy; Mark Cook
Journal:  Brain Pathol       Date:  2009-02-24       Impact factor: 6.508

Review 4.  Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy.

Authors:  Vassiliki Aroniadou-Anderjaska; Brita Fritsch; Felicia Qashu; Maria F M Braga
Journal:  Epilepsy Res       Date:  2008-01-15       Impact factor: 3.045

Review 5.  Neurobehavioral effects of levetiracetam in patients with traumatic brain injury.

Authors:  Jared F Benge; Richard A Phenis; Abigail Bernett; Daniel Cruz-Laureano; Batool F Kirmani
Journal:  Front Neurol       Date:  2013-12-02       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.